Zofran Lawsuit Claims Drug Caused Tetralogy Of Fallot

November 06, 2015 – – ZofranLegal.com reports on another lawsuit filed against GlaoSmithKline and their anti-nausea drug Zofran. This suit was filed by parents from Highland, Illinois, under case number 3:15-cv-00787 in the U.S. District Court for the Southern District of Illinois. Details found within the suit allege that because the mother took Zofran while pregnant and exposed the child to the drug while he was developing in utero, he was born with a rare combination of congenital heart defects termed Tetralogy of Fallot.

Additional details in the documents state that the boy’s mother was first given Zofran through an IV, and later continued to take the drug in tablet form to combat morning sickness during her first trimester. Unfortunately, this is also the time when a fetus’ heart tissue does much of its developing. The son, who was born in 2006, was very quickly diagnosed with Tetralogy of Fallot. It was a condition which was considered both serious and complex, and would require surgery when the boy was deemed strong enough.

Today, at age 9, the boy has undergone open heart surgery and several other procedures. His condition is marked by four congenital heart defects, all accompanying each other, and has been deemed possibly permanent and/or fatal. Allegations state that, just as a series of epidemiological studies have noted, their son was put at an increased risk for these congenital heart defects by having been exposed to Zofran while developing in utero.

The parents in this situation are unfortunately not alone. Across the U.S., over 60 other parents have also stepped forward, filing lawsuits against GlaxoSmithKline regarding Zofran Birth Defects. Allegations include that the drug caused defects in infants ranging from cleft lip and palate, to atrial septal defect, ventricular septal defect, transposition of the greater vessels, and tetralogy of fallot. Others allege club foot and kidney defects.

It has been noted in many of the suits that GlaxoSmithKline’s drug Zofran was never approved by the FDA for the treatment of morning sickness in pregnant women. It was instead approved to treat those experiencing nausea after chemotherapy, radiation, or anesthesia. Despite this fact, GSK marketed the product directly to Ob/Gyns for the treatment of morning sickness, and it has since been prescribed to countless pregnant mothers.

For these reasons, it is expected that additional Zofran Birth Defect lawsuits will be filed. The attorneys at Monheit Law are currently working to ensure that any mother who was prescribed Zofran while pregnant and subsequently gave birth to a child with defects has the option to explore all of their rights. These individuals and their children may be entitled to compensation. Monheit Law offers confidential and completely free consultations.

For additional information on this topic, or to ask questions, contact Attorney Michael Monheit by calling 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005183